12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

BioVersys AG, GlaxoSmithKline, Wellcome Trust deal

BioVersys and GlaxoSmithKline partnered to develop a preclinical compound and two backup compounds to treat tuberculosis (TB). BioVersys has been developing the compounds, which are designed to improve the efficacy of existing TB drug ethionamide, since 2013 with a consortium that includes the University...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >